Prostate-specific antigen-based screening for prostate cancer evidence report and systematic review for the us preventive services task force

JAMA - Journal of the American Medical Association

Volumn 319, Issue 18, 2018, Pages 1914-1931

  Fenton, Joshua J ^a   Weyrich, Meghan S ^a   Durbin, Shauna ^a   Liu, Yu ^b   Bang, Heejung ^b   Melnikow, Joy ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER SCREENING; CAUSE OF DEATH; CONSERVATIVE TREATMENT; DIAGNOSTIC ERROR; DISEASE SURVEILLANCE; ERECTILE DYSFUNCTION; EVIDENCE BASED PRACTICE; FALSE POSITIVE RESULT; HOSPITALIZATION; HUMAN; IATROGENIC DISEASE; MAJOR CLINICAL STUDY; MALE; METASTASIS; MORTALITY RISK; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; RISK REDUCTION; SYSTEMATIC REVIEW; TUMOR BIOPSY; URINE INCONTINENCE; WATCHFUL WAITING; AGE; BIOPSY; BLOOD; EARLY CANCER DIAGNOSIS; HEALTH SERVICE; MIDDLE AGED; MORTALITY; PRACTICE GUIDELINE; PROCEDURES; PROSTATE TUMOR; RISK FACTOR; STANDARDS;

AGE FACTORS; AGED; BIOPSY; EARLY DETECTION OF CANCER; FALSE POSITIVE REACTIONS; HUMANS; MALE; MEDICAL OVERUSE; MIDDLE AGED; PRACTICE GUIDELINES AS TOPIC; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK FACTORS; WATCHFUL WAITING;

EID: 85046805131     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2018.3712     Document Type: Review

References (107)

1. National Cancer Institute. SEER Cancer Statistics Factsheets: prostate cancer. https://seer.cancer.gov/statfacts/html/prost.html. Accessed July 24, 2017.
2. American Cancer Society. Cancer Facts & Figures 2018. Atlanta: American Cancer Society; 2018.
3. Kiciński M, Vangronsveld J, Nawrot TS. An epidemiological reappraisal of the familial aggregation of prostate cancer: Ameta-Analysis. PLoS One. 2011;6(10):e27130.
4. Welch HG, Albertsen PC. Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005. J Natl Cancer Inst. 2009;101(19):1325-1329.
5. Lin JS, Petitti DB, Burda BU. Overview of Prostate Cancer Screening Decision Models: A Contextual Review for the U.S. Preventive Services Task Force. Rockville, MD: Agency for Healthcare Research and Quality; April 2017. AHRQ publication 17-05229-EF-2.
6. US Preventive Services Task Force.US Preventive Services Task Force Procedure Manual. AHRQ publication 08-05118-EF. https://www.uspreventiveservicestaskforce.org/Home/GetFile/6/7/procedure-manual-2015/pdf. Published 2015. Accessed May 24, 2016.
7. Chou R, Croswell JM, Dana T, et al. Screening for prostate cancer: A review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2011;155(11):762-771.
8. Lin K, Croswell JM, Koenig H, Lam C, Maltz A. Prostate-Specific Antigen-Based Screening for Prostate Cancer: An Evidence Update for the U.S. Preventive Services Task Force. Rockville, MD: Agency for Healthcare Resaerch and Quality; October 2011. AHRQ publication 12-05160-EF-1.
9. Wilt TJ, Jones KM, BarryMJ, et al. Follow-up of prostatectomy versus observation for early prostate cancer. N Engl J Med. 2017;377(2):132-142.
10. Chen RC, Basak R, Meyer AM, et al. Association between choice of radical prostatectomy, external beam radiotherapy, brachytherapy, or active surveillance and patient-reported quality of life among men with localized prostate cancer. JAMA. 2017;317(11):1141-1150.
11. Barocas DA, Alvarez J, Resnick MJ, et al. Association between radiation therapy, surgery, or observation for localized prostate cancer and patient-reported outcomes after 3 years. JAMA. 2017;317(11):1126-1140.
12. Gómez-Gómez E, Carrasco-Valiente J, Blanca-Pedregosa A, et al. European Randomized Study of Screening for Prostate Cancer risk calculator: external validation, variability, and clinical significance. Urology. 2017;102:85-91.
13. Maruf M, Fascelli M, George AK, et al. The prostate cancer prevention trial risk calculator 2.0 performs equally for standard biopsy and MRI/US fusion-guided biopsy. Prostate Cancer Prostatic Dis. 2017;20(2):179-185.
14. Park JY, Yoon S, Park MS, et al. Development and external validation of the Korean prostate cancer risk calculator for high-grade prostate cancer: comparison with twoWestern risk calculators in an Asian cohort. PLoS One. 2017;12(1): e0168917.
15. Martin RM, Donovan JL, Turner EL, et al; CAP Trial Group. Effect of a low-intensity PSA-based screening intervention on prostate cancer mortality: The CAP randomized clinical trial. JAMA. 2018;319(9):883-895.
16. Miller AB, Wall C, Baines CJ, Sun P, To T, Narod SA. Twenty five year follow-up for breast cancer incidence and mortality of the Canadian National Breast Screening Study: randomised screening trial. BMJ. 2014;348:g366.
17. Zackrisson S, Andersson I, Janzon L, Manjer J, Garne JP. Rate of over-diagnosis of breast cancer 15 years after end of Malmö mammographic screening trial: follow-up study. BMJ. 2006;332 (7543):689-692.
18. Carter JL, Coletti RJ, Harris RP. Quantifying and monitoring overdiagnosis in cancer screening: A systematic review of methods. BMJ. 2015;350: g7773.
19. Patz EF Jr, Pinsky P, Gatsonis C, et al; NLST Overdiagnosis ManuscriptWriting Team. Overdiagnosis in low-dose computed tomography screening for lung cancer. JAMA Intern Med. 2014; 174(2):269-274.
20. Wells GA, Shea B, OConnell D, et al. The Newcastle-Ottowa Scale (NOS) for assessing the quality of nonrandomised studies in meta-Analysis. http://www.ohri.ca/programs/clinical-epidemiology/oxford.asp. Published 2016. Accessed August 16, 2016.
21. National Institute for Health and Care Excellence. The Guidelines Manual. London, United Kingdom: National Institute for Health and Care Excellence; 2006.
22. Moons KG, de Groot JA, BouwmeesterW, et al. Critical appraisal and data extraction for systematic reviews of prediction modelling studies: The CHARMS checklist. PLoS Med. 2014;11(10):e1001744.
23. Collins GS, Reitsma JB, Altman DG, Moons KG. Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis (TRIPOD): The TRIPOD statement. Ann Intern Med. 2015;162(1):55-63.
24. Kjellman A, Akre O, Norming U, Törnblom M, Gustafsson O. 15-year followup of a population based prostate cancer screening study. J Urol. 2009;181(4):1615-1621.
25. Labrie F, Candas B, Cusan L, et al. Screening decreases prostate cancer mortality: 11-year follow-up of the 1988 Quebec prospective randomized controlled trial. Prostate. 2004;59(3): 311-318.
26. Sandblom G, Varenhorst E, Rosell J, Löfman O, Carlsson P. Randomised prostate cancer screening trial: 20 year follow-up. BMJ. 2011;342:d1539.
27. Andriole GL, Crawford ED, Grubb RL III, et al; PLCO Project Team. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med. 2009;360(13):1310-1319.
28. Schröder FH, Hugosson J, Roobol MJ, et al; ERSPC Investigators. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009;360(13):1320-1328.
29. Pinsky PF, Prorok PC, Yu K, et al. Extended mortality results for prostate cancer screening in the PLCO trial with median follow-up of 15 years. Cancer. 2017;123(4):592-599.
30. Schröder FH, Hugosson J, Roobol MJ, et al; ERSPC Investigators. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet. 2014;384(9959): 2027-2035.
31. Ciatto S, Zappa M, Villers A, Paez A, Otto SJ, Auvinen A. Contamination by opportunistic screening in the European Randomized Study of Prostate Cancer Screening. BJU Int. 2003;92(suppl 2):97-100.
32. Arnsrud Godtman R, Holmberg E, Lilja H, Stranne J, Hugosson J. Opportunistic testing versus organized prostate-specific antigen screening: outcome after 18 years in the Göteborg randomized population-based prostate cancer screening trial. Eur Urol. 2015;68(3):354-360.
33. Hugosson J, Carlsson S, Aus G, et al. Mortality results from the Göteborg randomised population-based prostate-cancer screening trial. Lancet Oncol. 2010;11(8):725-732.
34. Luján M, Páez A, Angulo JC, et al. Prostate cancer incidence and mortality in the Spanish section of the European Randomized Study of Screening for Prostate Cancer (ERSPC). Prostate Cancer Prostatic Dis. 2014;17(2):187-191.
35. Roobol MJ, Kranse R, Bangma CH, et al; ERSPC Rotterdam Study Group. Screening for prostate cancer: results of the Rotterdam section of the European randomized study of screening for prostate cancer. Eur Urol. 2013;64(4):530-539.
36. Bokhorst LP, Bangma CH, van Leenders GJ, et al. Prostate-specific antigen-based prostate cancer screening: reduction of prostate cancer mortality after correction for nonattendance and contamination in the Rotterdam section of the European Randomized Study of Screening for Prostate Cancer. Eur Urol. 2014;65(2):329-336.
37. Kilpeläinen TP, Tammela TL, Malila N, et al. Prostate cancer mortality in the Finnish randomized screening trial. J Natl Cancer Inst. 2013;105(10):719-725.
38. Kilpeläinen TP, Pogodin-Hannolainen D, Kemppainen K, et al. Estimate of opportunistic prostate-specific antigen testing in the Finnish Randomized Study of Screening for Prostate Cancer. J Urol. 2017;198(1):50-57.
39. Andriole GL, Crawford ED, Grubb RL III, et al; PLCO Project Team. Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. J Natl Cancer Inst. 2012; 104(2):125-132.
40. Cuzick J, Thorat MA, Andriole G, et al. Prevention and early detection of prostate cancer. Lancet Oncol. 2014;15(11):e484-e492.
41. Pinsky PF, Blacka A, Kramer BS, Miller A, Prorok PC, Berg C. Assessing contamination and compliance in the prostate component of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. Clin Trials. 2010;7(4):303-311.
42. Young GJ, Harrison S, Turner EL, et al. Prostate-specific antigen (PSA) testing of men in UK general practice: A 10-year longitudinal cohort study. BMJ Open. 2017;7(10):e017729.
43. Schröder FH, Hugosson J, Carlsson S, et al. Screening for prostate cancer decreases the risk of developingmetastatic disease: findings from the European Randomized Study of Screening for Prostate Cancer (ERSPC). Eur Urol. 2012;62(5):745-752.
44. Liss MA, Chen H, Hemal S, et al. Impact of family history on prostate cancer mortality in white men undergoing prostate specific antigen based screening. J Urol. 2015;193(1):75-79.
45. Bokhorst LP, Zhu X, Bul M, Bangma CH, Schröder FH, Roobol MJ. Positive predictive value of prostate biopsy indicated by prostate-specificantigen-based prostate cancer screening: Trends over time in a European randomized trial. BJU Int. 2012;110(11):1654-1660.
46. Brindle LA, Oliver SE, Dedman D, et al. Measuring the psychosocial impact of population-based prostate-specific antigen testing for prostate cancer in the UK. BJU Int. 2006;98(4): 777-782.
47. Carlsson SV, Holmberg E, Moss SM, et al. No excess mortality after prostate biopsy: results from the European Randomized Study of Screening for Prostate Cancer. BJU Int. 2011;107(12):1912-1917.
48. Fowler FJ Jr, BarryMJ, Walker-Corkery B, et al. The impact of a suspicious prostate biopsy on patients psychological, socio-behavioral, and medical care outcomes. J Gen Intern Med. 2006;21 (7):715-721.
49. Katz DA, Jarrard DF, McHorney CA, Hillis SL, Wiebe DA, Fryback DG. Health perceptions in patients who undergo screening and workup for prostate cancer. Urology. 2007;69(2):215-220.
50. Kilpeläinen TP, Tammela TL, Roobol M, et al. False-positive screening results in the European randomized study of screening for prostate cancer. Eur J Cancer. 2011;47(18):2698-2705.
51. McNaughton-Collins M, Fowler FJ Jr, Caubet JF, et al. Psychological effects of a suspicious prostate cancer screening test followed by a benign biopsy result. Am J Med. 2004;117(10):719-725.
52. Pinsky PF, Parnes HL, Andriole G. Mortality and complications after prostate biopsy in the Prostate, Lung, Colorectal and Ovarian Cancer Screening (PLCO) trial. BJU Int. 2014;113(2):254-259.
53. Rosario DJ, Lane JA, Metcalfe C, et al. Short term outcomes of prostate biopsy in men tested for cancer by prostate specific antigen: prospective evaluation within ProtecT study. BMJ. 2012;344:d7894.
54. Vasarainen H, Malmi H, Määttänen L, et al. Effects of prostate cancer screening on health-related quality of life: results of the Finnish arm of the European Randomized Screening Trial (ERSPC). Acta Oncol. 2013;52(8):1615-1621.
55. Walter LC, Fung KZ, Kirby KA, et al. Five-year downstream outcomes following prostate-specific antigen screening in older men. JAMA Intern Med. 2013;173(10):866-873.
56. Croswell JM, Kramer BS, Kreimer AR, et al. Cumulative incidence of false-positive results in repeated, multimodal cancer screening. Ann Fam Med. 2009;7(3):212-222.
57. Raaijmakers R, KirkelsWJ, Roobol MJ, Wildhagen MF, Schrder FH. Complication rates and risk factors of 5802 transrectal ultrasound-guided sextant biopsies of the prostate within a population-based screening program. Urology. 2002;60(5):826-830.
58. Hamdy FC, Donovan JL, Lane JA, et al; ProtecT Study Group. 10-Year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. N Engl J Med. 2016;375(15):1415-1424.
59. Bill-Axelson A, Holmberg L, Garmo H, et al. Radical prostatectomy or watchful waiting in early prostate cancer. N Engl J Med. 2014;370(10):932-942.
60. Ladjevardi S, Sandblom G, Berglund A, Varenhorst E. Tumour grade, treatment, and relative survival in a population-based cohort of men with potentially curable prostate cancer. Eur Urol. 2010;57(4):631-638.
61. SchymuraMJ, Kahn AR, German RR, et al. Factors associated with initial treatment and survival for clinically localized prostate cancer: results from the CDC-NPCR Patterns of Care Study (PoC1). BMC Cancer. 2010;10:152.
62. Stattin P, Holmberg E, Johansson JE, Holmberg L, Adolfsson J, Hugosson J; National Prostate Cancer Register (NPCR) of Sweden. Outcomes in localized prostate cancer: National Prostate Cancer Register of Sweden follow-up study. J Natl Cancer Inst. 2010;102(13):950-958.
63. Zhou EH, Ellis RJ, Cherullo E, et al. Radiotherapy and survival in prostate cancer patients: A population-based study. Int J Radiat Oncol Biol Phys. 2009;73(1):15-23.
64. Albertsen PC, Hanley JA, Penson DF, Barrows G, Fine J. 13-year outcomes following treatment for clinically localized prostate cancer in a population based cohort. J Urol. 2007;177(3):932-936.
65. Wong YN, Mitra N, Hudes G, et al. Survival associated with treatment vs observation of localized prostate cancer in elderly men. JAMA. 2006;296(22):2683-2693.
66. Donovan JL, Hamdy FC, Lane JA, et al; ProtecT Study Group. Patient-reported outcomes after monitoring, surgery, or radiotherapy for prostate cancer. N Engl J Med. 2016;375(15):1425-1437.
67. Fransson P, Damber JE, Widmark A. Health-related quality of life 10 years after external beam radiotherapy or watchful waiting in patients with localized prostate cancer. Scand J Urol Nephrol. 2009;43(2):119-126.
68. Wilt TJ, Brawer MK, Jones KM, et al; Prostate Cancer Intervention versus Observation Trial (PIVOT) Study Group. Radical prostatectomy Versus observation for localized prostate cancer. N Engl J Med. 2012;367(3):203-213.
69. Hoffman RM, HuntWC, Gilliland FD, Stephenson RA, Potosky AL. Patient satisfaction with treatment decisions for clinically localized prostate carcinoma: results from the Prostate Cancer Outcomes Study. Cancer. 2003;97(7):1653-1662.
70. Litwin MS, Lubeck DP, Spitalny GM, Henning JM, Carroll PR. Mental health in men treated for early stage prostate carcinoma: A posttreatment, longitudinal quality of life analysis from the Cancer of the Prostate Strategic Urologic Research Endeavor. Cancer. 2002;95(1):54-60.
71. Bacon CG, Giovannucci E, TestaM, Kawachi I. The impact of cancer treatment on quality of life outcomes for patients with localized prostate cancer. J Urol. 2001;166(5):1804-1810.
72. Lubeck DP, Litwin MS, Henning JM, Stoddard ML, Flanders SC, Carroll PR. Changes in health-related quality of life in the first year after treatment for prostate cancer: results from CaPSURE. Urology. 1999;53(1):180-186.
73. Litwin MS. Health-related quality of life after treatment for localized prostate cancer. Cancer. 1995;75(S7):2000-2003.
74. Litwin MS, Hays RD, Fink A, et al. Quality-of-life outcomes in men treated for localized prostate cancer. JAMA. 1995;273(2):129-135.
75. Schapira MM, Lawrence WF, Katz DA, McAuliffe TL, Nattinger AB. Effect of treatment on quality of life among men with clinically localized prostate cancer. Med Care. 2001;39(3):243-253.
76. Siegel T, Moul JW, SpevakM, AlvordWG, Costabile RA. The development of erectile dysfunction in men treated for prostate cancer. J Urol. 2001;165(2):430-435.
77. Smith DP, KingMT, Egger S, et al. Quality of life three years after diagnosis of localised prostate cancer: population based cohort study. BMJ. 2009; 339:b4817.
78. Smith DS, Carvalhal GF, Schneider K, Krygiel J, Yan Y, CatalonaWJ. Quality-of-life outcomes for men with prostate carcinoma detected by screening. Cancer. 2000;88(6):1454-1463.
79. Alibhai SM, Leach M, Tomlinson G, et al. 30-day mortality and major complications after radical prostatectomy: influence of age and comorbidity. J Natl Cancer Inst. 2005;97(20):1525-1532.
80. Augustin H, Hammerer P, Graefen M, et al. Intraoperative and perioperative morbidity of contemporary radical retropubic prostatectomy in a consecutive series of 1243 patients: results of a single center between 1999 and 2002. Eur Urol. 2003;43(2):113-118.
81. Björklund J, Folkvaljon Y, Cole A, et al. Postoperative mortality 90 days after robot-Assisted laparoscopic prostatectomy and retropubic radical prostatectomy: A nationwide population-based study. BJU Int. 2016;118(2):302-306.
82. Rabbani F, Yunis LH, Pinochet R, et al. Comprehensive standardized report of complications of retropubic and laparoscopic radical prostatectomy. Eur Urol. 2010;57(3):371-386.
83. Walz J, Montorsi F, Jeldres C, et al. The effect of surgical volume, age and comorbidities on 30-day mortality after radical prostatectomy: A population-based analysis of 9208 consecutive cases. BJU Int. 2008;101(7):826-832.
84. Yao SL, Lu-Yao G. Population-based study of relationships between hospital volume of prostatectomies, patient outcomes, and length of hospital stay. J Natl Cancer Inst. 1999;91(22):1950-1956.
85. Fransson P, Damber JE, Tomic R, Modig H, Nyberg G, Widmark A. Quality of life and symptoms in a randomized trial of radiotherapy versus deferred treatment of localized prostate carcinoma. Cancer. 2001;92(12):3111-3119.
86. ThongMS, Mols F, Kil PJ, Korfage IJ, van de Poll-Franse LV. Prostate cancer survivors who would be eligible for active surveillance but were either treated with radiotherapy or managed expectantly: comparisons on long-Term quality of life and symptom burden. BJU Int. 2010;105(5): 652-658.
87. Shah C, Jones PM, Wallace M, et al. Differences in disease presentation, treatment outcomes, and toxicities in African American patients treated with radiation therapy for prostate cancer.AmJ Clin Oncol. 2012;35(6):566-571.
88. Johansson E, Steineck G, Holmberg L, et al; SPCG-4 Investigators. Long-Term quality-of-life outcomes after radical prostatectomy or watchful waiting: The Scandinavian Prostate Cancer Group-4 randomised trial. Lancet Oncol. 2011;12(9):891-899.
89. Foley RW, Maweni RM, Gorman L, et al. European Randomised Study of Screening for Prostate Cancer (ERSPC) risk calculators significantly outperform the Prostate Cancer Prevention Trial (PCPT) 2.0 in the prediction of prostate cancer: A multi-institutional study. BJU Int. 2016;118(5):706-713.
90. Poyet C, Nieboer D, Bhindi B, et al. Prostate cancer risk prediction using the novel versions of the European Randomised Study for Screening of Prostate Cancer (ERSPC) and Prostate Cancer Prevention Trial (PCPT) risk calculators: independent validation and comparison in a contemporary European cohort. BJU Int. 2016;117 (3):401-408.
91. Lundon DJ, Kelly BD, Foley R, et al. Prostate cancer risk assessment tools in an unscreened population.World J Urol. 2015;33(6):827-832.
92. Ankerst DP, Hoefler J, Bock S, et al. Prostate Cancer Prevention Trial risk calculator 2.0 for the prediction of low-vs high-grade prostate cancer. Urology. 2014;83(6):1362-1367.
93. Ankerst DP, Boeck A, Freedland SJ, et al. Evaluating the Prostate Cancer Prevention Trial High Grade Prostate Cancer Risk Calculator in 10 international biopsy cohorts: results from the Prostate Biopsy Collaborative Group.World J Urol. 2014;32(1):185-191.
94. Roobol MJ, van Vugt HA, Loeb S, et al. Prediction of prostate cancer risk: The role of prostate volume and digital rectal examination in the ERSPC risk calculators. Eur Urol. 2012;61(3):577-583.
95. Nam RK, KattanMW, Chin JL, et al. Prospective multi-institutional study evaluating the performance of prostate cancer risk calculators. J Clin Oncol. 2011;29(22):2959-2964.
96. Ngo TC, Turnbull BB, Lavori PW, Presti JC Jr. The prostate cancer risk calculator from the Prostate Cancer Prevention Trial underestimates the risk of high grade cancer in contemporary referral patients. J Urol. 2011;185(2):483-487.
97. Trottier G, Roobol MJ, Lawrentschuk N, et al. Comparison of risk calculators from the Prostate Cancer Prevention Trial and the European Randomized Study of Screening for Prostate Cancer in a contemporary Canadian cohort. BJU Int. 2011; 108(8, pt 2):E237-E244.
98. Nguyen CT, Yu C, Moussa A, KattanMW, Jones JS. Performance of prostate cancer prevention trial risk calculator in a contemporary cohort screened for prostate cancer and diagnosed by extended prostate biopsy. J Urol. 2010;183(2): 529-533.
99. Hernandez DJ, Han M, Humphreys EB, et al. Predicting the outcome of prostate biopsy: comparison of a novel logistic regression-based model, the prostate cancer risk calculator, and prostate-specific antigen level alone. BJU Int. 2009; 103(5):609-614.
100. Tsodikov A, Gulati R, Heijnsdijk EAM, et al. Reconciling the effects of screening on prostate cancer mortality in the ERSPC and PLCO trials. Ann Intern Med. 2017;167(7):449-455.
101. Zappa M, Ciatto S, Bonardi R, Mazzotta A. Overdiagnosis of prostate carcinoma by screening: An estimate based on the results of the Florence Screening Pilot Study. Ann Oncol. 1998;9(12):1297-1300.
102. Draisma G, Boer R, Otto SJ, et al. Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst. 2003;95(12):868-878.
103. Draisma G, Etzioni R, Tsodikov A, et al. Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context. J Natl Cancer Inst. 2009;101(6):374-383.
104. Etzioni R, Penson DF, Legler JM, et al. Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst. 2002;94(13): 981-990.
105. Tosoian JJ, Carter HB, Lepor A, Loeb S. Active surveillance for prostate cancer: current evidence and contemporary state of practice. Nat Rev Urol. 2016;13(4):205-215.
106. Carroll PR, Parsons JK, Andriole G, et al. NCCN Guidelines Insights: prostate cancer early detection, version 2.2016. J Natl Compr Canc Netw. 2016;14 (5):509-519.
107. Wolters T, Roobol MJ, Steyerberg EW, et al. The effect of study arm on prostate cancer treatment in the large screening trial ERSPC. Int J Cancer. 2010;126(10):2387-2393.